Oxurion NV - Additional Topline Data from Positive Phase 1 Trial
with THR-687 in Patients with Diabetic Macular Edema (DME)
to be Presented at the Upcoming Angiogenesis, Exudation, and Degeneration 2020 Conference
THR-687, a potent pan-RGD integrin inhibitor, holds potential to become a new standard of care for patients with DME
Leuven, Belgium, 5 February 2020 - 07.00 AM CET - Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company developing next generation therapies for patients with diabetic eye disease, today announces that a presentation of further data from a Phase 1 study with THR-687 in patients with diabetic macular edema (DME) will be given at the Angiogenesis, Exudation, and Degeneration 2020 conference being held on February 8, 2020, in Miami, US.
The presentation will be made by Arshad Khanani, M.D., M.A., Director of Clinical Research at Sierra Eye Associates, Reno, Nevada, US, one of the investigators of the THR-687 Phase 1 study.
Details of the presentation are as follows:
Title: Results of a Phase 1 Study Using the Integrin Antagonist THR-687 in Patients with DME
Date/time: February 8; 5.08 pm EST
Session title: Diabetes, Uveitis, and Retinal Degenerations
END
For further information please contact:
| Oxurion NV Wouter Piepers, Global Head of Investor Relations & Corporate Communications Tel: +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@oxurion.com (mailto:wouter.piepers@oxurion.com) | Citigate Dewe Rogerson David Dible/ Sylvie Berrebi/Frazer Hall Tel: +44 20 7638 9571 oxurion@citigatedewerogerson.com (mailto:thrombogenics@citigatedewerogerson.com) |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care therapies, which are designed to better preserve vision in patients with diabetic eye disease, the leading cause of blindness in people of working age worldwide.
Oxurion's clinical pipeline comprises:
- THR-149, a plasma kallikrein inhibitor being developed as a potential new standard of care for DME patients who respond sub-optimally to anti-VEGF therapy.
THR-149 has shown positive topline Phase 1 results for the treatment of DME. The Company is currently preparing to conduct a Phase 2 clinical program, which is expected to start in H1 2020. THR-149 was developed in conjunction with Bicycle Therapeutics plc (NASDAQ: BCYC)
- THR-687, is a pan-RGD integrin inhibitor, that is being developed as a potential new standard of care for all DME patients
Positive topline results in a Phase 1 clinical study assessing it as a treatment for DME were announced in January 2020. THR-687 is expected to enter a Phase 2 clinical trial in H2 2020. THR-687 is an optimized compound derived from a broader library of integrin inhibitors in-licensed from Galapagos nv (Euronext & NASDAQ: GLPG).
Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.
More information is available at www.oxurion.com
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
